NasdaqCM - Delayed Quote USD

Immatics N.V. (IMTXW)

Compare

0.0134

+0.0009

+(7.20%)

At close: April 17 at 4:00:00 PM EDT

Immatics Full Year 2024 Earnings: Beats Expectations

Immatics ( NASDAQ:IMTX ) Full Year 2024 Results Key Financial Results Revenue: €155.8m (up 189% from FY 2023). Net...

Simply Wall St. 22 days ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Announces Full Year 2024 Financial Results and Business Update

Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203 TCR-T (PRAME): Phase 1b IMA203 data published in October 2024 demonstrated a confirmed ORR of 54%, 12.1 months mDOR, 6 months mPFS and OS not reached at a mFU time of 8.6 months in advanced melanoma patients; next data update on Phase 1b trial with extended follow-up planned in 2025 Second-generation

GlobeNewswire 23 days ago

IMTX
+3.65%
IMTXW
+7.20%
Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year

Investing in stocks comes with the risk that the share price will fall. Anyone who held Immatics N.V. ( NASDAQ:IMTX...

Simply Wall St. 2 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Immatics N.V. ( NASDAQ:IMTX ) defied analyst predictions to release its third-quarter results, which were ahead of...

Simply Wall St. 4 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Sees Revenue Surge Despite R&D Expenses

Immatics (IMTX) has released an update. Immatics reported a significant increase in collaboration revenue for the nine months ending September 30, 2024, reaching €99.6 million compared to €38.1 million in the same period last year. Despite higher revenue, the company faced substantial research and development expenses, which contributed to a loss before taxes of €2.4 million for Q3 2024. Investors should note the company’s ongoing focus on R&D, which may impact financial performance in the near

TipRanks 4 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical data from the TCR Bispecific molecule, TCER® IMA402 targeting PRAME, in the Phase 1 dose escalation trial, demonstrating a favorable tolerability profile and signs of dose-dependent and PRAME expression-dependent clinical activity, including first objective responses in melanoma patients; early pharmacokin

GlobeNewswire 4 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T PRAME franchise to target solid cancers ACTengine® IMA203 demonstrates 54% cORR, 12.1 months mDOR and 6 months mPFS in heavily pretreated metastatic melanoma patients and >1-year mPFS in patients with deep responses; Company plans to start its randomized-controlled Phase 3 SUPRAME trial in December 2024 to evaluate IMA203 in second-line or

GlobeNewswire 5 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50%

Key Insights Significantly high institutional ownership implies Immatics' stock price is sensitive to their trading...

Simply Wall St. 5 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Advances IMA203 to Phase 3 Trial in Melanoma

Immatics (IMTX) has released an update. Immatics has reported promising updated Phase 1b clinical data for its ACTengine IMA203 therapy targeting PRAME in metastatic melanoma, with a 54% objective response rate and median duration of response over 12 months. Following favorable Phase 1b outcomes, including 6 months median progression-free survival (PFS) and overall survival not yet reached, Immatics is advancing to a Phase 3 trial, SUPRAME, to further assess IMA203’s efficacy. The SUPRAME trial

TipRanks 6 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Announces Pricing of $150 Million Public Offering

Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are e

GlobeNewswire 6 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Announces Proposed $150 Million Public Offering

Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the commencement of an underwritten public offering of its ordinary shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or term

GlobeNewswire 6 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data update in May 2024 and provides the first report on progression-free survival (PFS) and overall survival (OS)Based on the Phase 1b data, the Company will proceed directly to a registration-enabling Phase 3

GlobeNewswire 6 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics N.V. (IMTX) Receives Buy Rating from Analysts

We recently published a list of 10 Best Biotech Stocks To Buy Under $20. In this article, we are going to take a look at where Immatics N.V. (NASDAQ:IMTX) stands against the other best biotech stocks to buy under $20. The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, technological […]

Insider Monkey 6 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024. Full abstracts will be available on November 5, 2024, at 9:00 am EST in the JITC Sup

GlobeNewswire 6 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on various solid cancersData from the first-in-human Phase 1 dose escalation trial demonstrate initial anti-tumor activity and a manageable tolerability profile for TCER® IMA401 monotherapy; patient population includes 35 heavily pre-treated patients across 16 different solid tumor types; dose escalation

GlobeNewswire 6 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that updated clinical data on its lead cell therapy candidate, ACTengine® IMA203 targeting PRAME, will be presented at the 21st International Congress of the Society for Melanoma Research. Oral presentation Date / Time: October 11, 2024

GlobeNewswire 7 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Second Quarter 2024 Earnings: Beats Expectations

Immatics ( NASDAQ:IMTX ) Second Quarter 2024 Results Key Financial Results Revenue: €18.8m (down 16% from 2Q 2023). Net...

Simply Wall St. 7 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Announces Second Quarter 2024 Financial Results and Business Update

Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, median duration of response of 13.5 months; IMA203 continues to maintain a favorable tolerability profileRegistration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 in 2L+ melanoma planned to commence in 2024 Next data update on IMA203 and IMA203CD8 (GEN2) to be presented at medical conferences in 2H 2024First Phase 1 d

GlobeNewswire 8 months ago

IMTX
+3.65%
IMTXW
+7.20%
Immatics Appoints Alise Reicin to Board of Directors

Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the appointment of Alise Reicin, M.D., to its Board of Directors. Alise Reicin is an experienced and expert pharmaceutical industry executive and leader who has led the development of multiple important new therapies, including Keytruda®. Dr

GlobeNewswire 8 months ago

IMTX
+3.65%
IMTXW
+7.20%
Investors in Immatics (NASDAQ:IMTX) have seen returns of 24% over the past five years

The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up...

Simply Wall St. 8 months ago

IMTX
+3.65%
IMTXW
+7.20%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Immatics N.V. (IMTXW)

Immatics Full Year 2024 Earnings: Beats Expectations

Immatics Announces Full Year 2024 Financial Results and Business Update

Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year

Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Immatics Sees Revenue Surge Despite R&D Expenses

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50%

Immatics Advances IMA203 to Phase 3 Trial in Melanoma

Immatics Announces Pricing of $150 Million Public Offering

Immatics Announces Proposed $150 Million Public Offering

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Immatics N.V. (IMTX) Receives Buy Rating from Analysts

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Immatics Second Quarter 2024 Earnings: Beats Expectations

Immatics Announces Second Quarter 2024 Financial Results and Business Update

Immatics Appoints Alise Reicin to Board of Directors

Investors in Immatics (NASDAQ:IMTX) have seen returns of 24% over the past five years